Radical Numerics says its AI-designed phage was given to a patient
California-based Radical Numerics says its Omnii-1 system designed bacteriophages that were synthesised and administered to a patient with an antibiotic-resistant infection through an authorised compassionate-use pathway. The company has not disclosed the clinical outcome, and its claim is awaiting peer-reviewed scrutiny, The Independent reports.
Bottom line — Omnii-1’s first reported human use has no disclosed outcome and is not yet backed by a peer-reviewed study.
Go deeper 6
-
Phages are viruses that target specific bacteria; The Independent notes this selectivity can spare beneficial gut microbes affected by broad-spectrum antibiotics.
-
Radical Numerics says its model uses genomic sequences, phage genomes and data on phage-host interactions to identify or design candidate phages.
-
The company says it tested the recovery and activity of designed variants against bacterial strains before selecting candidates.
-
Technology Networks reports that phage therapies are being developed for cystic fibrosis lung infections, where antibiotic resistance can leave some patients with few options.
-
For cystic fibrosis, developers face challenges including delivery through mucus and biofilms, choosing meaningful trial endpoints and fitting treatment into patients’ routines, Technology Networks says.
-
Technology Networks notes that the UK Medicines and Healthcare products Regulatory Agency issued therapeutic-phage guidance in 2025, while shared evidence standards are still needed.